Physician profile
Mitchell Kline
NPI 1932136231
$3,759.29
in general payments reported to CMS, 2019-2025
25 companies · $533 in 2025
The $533 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $649 · 2021: $290 · 2022: $720 · 2023: $623 · 2024: $555 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,000.83 | 2019-2025 | Aklief |
| Sun Pharmaceutical Industries INC. | $558.82 | 2019-2025 | Odomzo, Blu-U, Winlevi |
| Leo Pharma INC. | $350.76 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $311.44 | 2023-2025 | |
| Incyte Corporation | $211.64 | 2021-2025 | Opzelura |
| Pfizer INC. | $205.06 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $170.33 | 2022-2025 | Libtayo, Dupixent |
| Allergan, INC. | $156.94 | 2019-2022 | |
| Lilly USA, LLC | $156.35 | 2023-2024 | Taltz, Olumiant |
| Amgen INC. | $99.62 | 2023-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $79.68 | 2021-2023 | |
| Dusa Pharmaceuticals, INC. | $60.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.16 | 2023-2025 | |
| Organon LLC | $52.73 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.69 | 2024 | Siliq, Duobrii |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sebela Pharmaceuticals INC. | $39.67 | 2021-2022 | |
| Revance Therapeutics, INC. | $31.13 | 2024 | Daxxify |
| Dermavant Sciences, INC. | $26.85 | 2023 | Vtama |
| Janssen Biotech, INC. | $25.11 | 2024 | Tremfya |
| Epi Health, LLC | $22.61 | 2022 | |
| Genentech USA, INC. | $20.90 | 2019 | |
| Aclaris Therapeutics, INC. | $20.83 | 2019 | |
| Fidia Pharma USA INC. | $19.48 | 2024 | |
| Arcutis Biotherapeutics, INC. | $18.57 | 2023 | |
| Journey Medical Corporation | $14.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Kline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.